Studying resistance to IgA nephropathy treatments in real life
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study observes how people with IgA nephropathy respond to standard and newer treatments in everyday medical practice, to understand why some cases are resistant to therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You had a kidney biopsy after 2017 that confirmed IgA nephropathy
- You agree to allow your medical data to be used for research
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called MY008211A for people with IgA nephropathy (a kidney disease). It aims to see if it can safely reduce protein in the urine and protect kidney function.
This phase 2a trial tests an experimental drug called RG002C0106 in people with primary IgA nephropathy. The goal is to see if the drug can reduce protein in the urine and protect kidney function.
This trial tests an experimental tablet, HSK39297, for people with IgA nephropathy, a kidney disease. It aims to see if the drug is safe and can help reduce protein in the urine, which is a sign of kidney damage.
This trial tests whether choosing treatment based on your personal kidney findings can improve outcomes in adults with IgA nephropathy (IgAN). It may help by matching therapy to the type and severity of kidney damage seen on biopsy.
This trial enrolls teens and adults with biopsy-proven IgA nephropathy to help doctors learn whether a specific care approach works better for high-quality treatment. It is meant for people whose IgA kidney disease is the primary form (not caused by another illness).
This study gathers information from people with IgA nephropathy to better understand how the disease changes over time and what can be expected. The goal is to improve care and help guide future treatments.
Hear when a new IgA Nephropathy (IgAN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.